ZL-1201
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
CD47
ZL-1201 (15 min) binds to CD47 on Jurkat cells[1].
ZL-1201 (10 μg/mL; 30 min) when combined with Trastuzumab (HY-P9907), Cetuximab (HY-P9905), or Rituximab (HY-P9913) significantly increases phagocytosis index compared to single agents or isotype control[1].
ZL-1201 (2 h) does not induce hemagglutination in whole blood[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice per week; 3–12 weeks
-
Result:Achieved >80% tumor growth inhibition (TGI) in Raji lymphoma xenografts; showed limited TGI (<50%) alone in solid tumor xenografts; significantly inhibited tumor growth when combined with therapeutic mAbs and chemotherapy, with triple combinations achieving maximal antitumor efficacy; increased intratumoral M1 macrophages, decreased M2 macrophages, and modulated cytokine release (increased TNFα/MCSF, decreased IL4) in the SKOV3 model
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ZL-1201 Related Classifications
HY-P991927 Related Classifications
Powered by Bioz